Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.

Scientific reports - 9 May 2016

Zhang Yun-Kai, Zhang Guan-Nan, Wang Yi-Jun, Patel Bhargav A, Talele Tanaji T, Yang Dong-Hua, Chen Zhe-Sheng

Abstract excerpt

ATP-Binding Cassette transporters are involved in the efflux of xenobiotic compounds and are responsible for decreasing drug accumulation in multidrug resistant (MDR) cells. Discovered by structure-based virtual screening algorithms, bafetinib, a Bcr-Abl/Lyn tyrosine kinase inhibitor, was found to have inhibitory effects on both ABCB1- and ABCG2-mediated MDR in this in-vitro investigation. Bafetinib significantly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2
Share to Doxorubicin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Drug Resistance, Multiple

Share to Fluorescence

Share to Mitoxantrone

Share to Paclitaxel

Share to Vanadates

Source

Open in PubMed Open full text

Identifiers

PMID: 27157787
DOI: 10.1038/srep25694
PMCID: PMC4860574

Genes

ABCB1
ABCG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.PMID 27157787Read ↗

Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells.Semantic proximity Read ↗

Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivoSemantic proximity Read ↗

ABC Transporter Inhibitors in Reversing Multidrug Resistance to ChemotherapySemantic proximity Read ↗

Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivoSemantic proximity Read ↗

Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studiesSemantic proximity Read ↗

Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistanceSemantic proximity Read ↗

Clinically-Relevant ABC Transporter for Anti-Cancer Drug ResistanceSemantic proximity Read ↗

Bufalin reverses ABCB1-mediated drug resistance in colorectal cancerSemantic proximity Read ↗

Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.Semantic proximity Read ↗

Interaction of Tyrosine Kinase Inhibitors with the MDR-Related ABC Transporter ProteinsSemantic proximity Read ↗

Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivoSemantic proximity Read ↗

Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.